Xilio Therapeutics, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Xilio Therapeutics, Inc. (XLO) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $134.00 thousand as of 2023-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2025-03-11
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $134.00K.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $219.00K.
- 2021-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $303.00K.
- 2020-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $388.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2023-12-31 | $134.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $219.00K 10-K · filed 2024-04-01 |
| 2021-12-31 | $303.00K 10-K · filed 2023-03-02 |
| 2020-12-31 | $388.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |